

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 3, 2006

Signature:

(Sharon M. Sirtich)

Docket No.: 9189 (A-947B)
01017/40451B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Manfred Brockhaus et al.

Application No.: 08/444,790

Filed: May 19, 1995

For: HUMAN TNF RECEPTOR



Confirmation No.: 5612

Art Unit: 1646

Examiner: Z. Howard

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. Copies of all the listed references are attached as Exhibits to the Amendment and Request for Reconsideration filed herewith. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

In accordance with 37 CFR §1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. In accordance with 37 CFR §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 01017/40451B. A duplicate copy of this paper is enclosed.

Dated: October 3, 2006

Respectfully submitted,

By 
Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project (07-000-0000) persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	08/444,790
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1646
				Examiner Name	Z. Howard
Sheet	1	of	2	Attorney Docket Number	01017/40451B

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C162	Mohler et al., Soluble Tumor Necrosis Factor (TNF) Receptors are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists. <i>J. Immunol.</i> , 151:1548-1561 (1993)	
	C163	Sell, Immunology, Immunopathology and Immunity, 4 th Edition, Elsevier Science Publishing Co., New York, 1987, at pp. 85-91	
	C164	Bringman, Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes. <i>Hybridoma</i> , 6(5):489-507 (1987)	
	C165	Paul et al., Fundamental Immunology, 2 nd Edition, Paul, ed., Raven Press, New York, 1989, at pp. 679-701 and pp. 735-764.	
	C166	Smith et al., A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins, <i>Science</i> , 248:1019-1023, (1990)	
	C167	Wingfield et al., Tumour Necrosis Factor is a Compact Trimer, <i>FEBS Lett.</i> 211: 179-84 (1987)	
	C168	Smith and Baglioni, The Active Form of Tumor Necrosis Factor is a Trimer. <i>J. Biological Chemistry</i> , 262:6951-4 (1987)	
	C169	Larsson and Mosbach, Affinity Precipitation of Enzymes <i>FEBS Lett.</i> 98(2):333-338 (1979)	
	C170	Irwin and Tipton, Chapter 22, "Affinity Precipitation Methods" in <i>Methods in Mol. Bio.</i> , 59:217 (1996)	
	C171	Kohno et al., Presentation 1495, poster 271 presented at American College of Rheumatology Annual Meeting, November 13-17, 2005, San Diego, CA	
	C172	Klein, Immunology, 1 st Edition, Klein ed., Blackwell Scientific Publications, Cambridge, MA 1990 at pp. 446-447	
Examiner Signature			Date Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	08/444,790
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1646
				Examiner Name	Z. Howard
Sheet	2	of	2	Attorney Docket Number	01017/40451B

	C173	Byrn et al., Biological properties of a CD4 Immunoaderhesin, Nature, 344:667-670 (April 1990)	
	C174	Trauneecker et al., Highly Efficient Neutralization of HIV with Recombinant CD-4-Immunoglobulin Molecules, Nature 339:68-70, 1989	
	C175	Capon, Designing CD4 Immunoaderhesins for AIDS Therapy, Nature, 337:525-531 (1989)	
	C176	Barone et al., Comparative Analysis of the Ability of Entanercept and Inflixamab to Lyse TNF-Expressing Cells in a Complement-Dependent fashion, Arthritis Rheum., v42(9) supplement, September 1999	
	C177	Khare et al, Poster 715 presented at the Annual Meeting of the Society for Investigative Dermatology (SID), May 3-5, 2006, Philadelphia, PA	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--